Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
Division of Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya 663-8131, Japan.
Atsushi
A
Ogata
Masayasu
M
Kitano
Naoaki
N
Hashimoto
Tsuyoshi
T
Iwasaki
Teruaki
T
Hamano
Eizo
E
Kakishita
D000328:Adult; D019386:Alendronate / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001847:Bone Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D015675:Osteocalcin / Q000097:blood; D010014:Osteolysis / Q000188:drug therapy*; D010146:Pain / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology
D015415:Biomarkers; D015675:Osteocalcin; D019386:Alendronate